Testing a new treatment for breast cancer that resists hormone therapy
Pre-clinical testing the effects of MALT1 inhibitor on endocrine resistant breast cancer
This study is looking at how a new treatment that blocks a protein called MALT1 might help women with breast cancer that doesn't respond to hormone therapy, especially those with estrogen receptor-positive cancer, by potentially making their tumors more sensitive to the medication tamoxifen.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Louis University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10579334 on NIH RePORTER |
What this research studies
This research investigates the effects of a MALT1 inhibitor on breast cancer that is resistant to endocrine therapy, particularly in estrogen receptor-positive cases. The study aims to understand how blocking MALT1 can inhibit the growth of tamoxifen-resistant breast tumor cells and potentially restore their sensitivity to tamoxifen. By focusing on this specific target, the research seeks to develop new treatment strategies for patients who have not responded to standard hormone therapies. The approach includes pre-clinical testing to evaluate the effectiveness and safety of the MALT1 inhibitor in laboratory settings before considering clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are women with estrogen receptor-positive breast cancer who have developed resistance to endocrine therapy.
Not a fit: Patients with breast cancer that is not estrogen receptor-positive or those who have not undergone endocrine therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with hormone-resistant breast cancer, improving their chances of survival.
How similar studies have performed: Previous research targeting MALT1 in other cancers has shown promise, suggesting that this approach may also be effective in breast cancer treatment.
Where this research is happening
Saint Louis, United States
- Saint Louis University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Liu, Jianguo — Saint Louis University
- Study coordinator: Liu, Jianguo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.